Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Appointed director

KNIGHT KNOX DEVELOPMENT CORP. Create: Alert

All | News | Filings
Date FiledTypeDescription
09/06/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/15/2019 8-K Quarterly results
Docs: "Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update"
06/25/2019 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs: "Certificate of Change to the Articles of Incorporation of Artelo Biosciences, Inc",
"Artelo Biosciences Announces Pricing of $8.0 Million Public Offering and Uplisting to Nasdaq",
"Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option"
04/30/2019 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events
10/09/2018 8-K Quarterly results
09/14/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Series C Warrant",
"Form of Subscription Agreement",
"Form of Registration Rights Agreement"
05/30/2018 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Artelo Biosciences, Inc. Investor Presentation",
"ARTELO BIOSCIENCES COMMENCES TRADING ON OTCQB LA JOLLA, CA - May 30, 2018 - Artelo Biosciences, Inc. , a biopharmaceutical company focused on the development of therapeutic treatments that modulate the endocannabinoid system, is pleased to announce that as of May 21, 2018, its shares began trading on the OTCQB under the symbol ARTL. “The trading of Artelo’s shares on the OTCQB represents a significant strategic milestone that will help to enhance our visibility among the investor public,” said Gregory D. Gorgas, chief executive officer of Artelo Biosciences. “We look forward to sharing additional milestones in the coming months.” The OTCQB Venture Market offers early stage and developing companies the benefits of being publicly traded in the U.S. and streamlined market standards which enab..."
02/01/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Series B Warrant",
"Form of Registration Rights Agreement"
01/19/2018 8-K Entry into a Material Definitive Agreement
12/27/2017 8-K Completion of Acquisition or Disposition of Assets, Change in Shell Company Status, Financial Statements and Exhibits
12/22/2017 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Material and Data Transfer, Option and License Agreement between the Company and NEOMED Institute"
09/25/2017 8-K Quarterly results
08/04/2017 8-K Appointed a new director
Docs: "Form of Series A Warrant",
"Form of Subscription Agreement",
"Form of Registration Rights Agreement",
"Amendment to the Exclusive License Agreement between Artelo Biosciences, Inc. and Analog Sciences, Inc",
"Exclusive Patent License Agreement between Artelo Biosciences, Inc. and Analog Sciences, Inc",
"Indemnification Agreement",
"Stock Purchase Agreement"
05/16/2017 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Investor Presentation"
05/08/2017 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "EXCLUSIVE LICENSE AGREEMENT",
"Form of Indemnification Agreement",
"Note Repayment Agreement between Artelo Biosciences, Inc. and Malibu Investments Limited",
"Stock Purchase Agreement"
05/02/2017 8-K Form 8-K - Current report
04/17/2017 8-K Form 8-K - Current report
04/07/2017 8-K Form 8-K - Current report
02/09/2017 8-K Form 8-K - Current report
02/03/2017 8-K Form 8-K - Current report
11/18/2016 8-K Form 8-K - Current report
09/07/2016 8-K Termination of a Material Definitive Agreement
07/13/2016 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Letter of Intent"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy